ClinicalTrials.gg
CompletedNCT03589105PRO-MSACTIVEUpdated Jan 11, 2022

A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting

A Phase 4 interventional study of Ocrelizumab 300 mg and Ocrelizumab 600 mg in Multiple Sclerosis, sponsored by Hoffmann-La Roche. Completed at 46 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-11.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
423
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing ocrelizumab in Multiple Sclerosis — 3 open to participants now, 14 under way, 8 of them phase 3. ocrelizumab · Multiple Sclerosis.

Enrollment
8th of 27
423 · median 170
Started
2018
with 2 others
Phase 4
11 of 27
1 open now
Registered
5th of 27
by date
Lead sponsor
13 of 27
Hoffmann-La Roche

Among the 27 studies testing ocrelizumab in Multiple Sclerosis, this one is the 8th largest by enrollment, is one of 3 that started in 2018, is one of 11 in phase 4, and was the 5th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

3 of the 27 studies testing ocrelizumab in Multiple Sclerosis are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ocrelizumab

ocrelizumab: first FDA approval 2017 (OCREVUS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing ocrelizumab in Multiple Sclerosis, or all of them as a file.
02

Study summary

This national, open-label study is designed to give complementary efficacy, safety and patient reported outcomes (PROs) data in participants with active relapsing forms of MS. Participants will receive a maximum of 2 treatment cycles of ocrelizumab infusions: an initial dose of two 300 milligram (mg) infusions separated by 14 days followed by one single infusion of 600 mg ocrelizumab 24 weeks after the first infusion. Disease activity is determined by clinical relapses and/or Magnetic Resonance Imaging (MRI) activity.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >/=18 years at screening
  • Patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features: (i) at least one clinical relapse over a 6-month period prior to screening; (ii) AND/OR at least one T1 gadolinium-enhancing lesion or new and/or enlarging T2 lesion as detected by brain Magnetic Resonance Imaging (MRI) performed over a 3 months period prior to screening with no change of Disease-Modifying Treatment(s) (DMT) compared to a previous MRI performed within 24 months before screening
  • For women of : agreement to use an acceptable method during the treatment period and for at least 12 months after the last dose of ocrelizumab
  • Participants should be beneficiary of healthcare coverage under the social security system

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of primary progressive MS
  • Inability to complete an MRI ( for MRI include but are not restricted to weight ≥140 kg, pacemaker, cochlear implants, presence of foreign substances in the eye, intracranial vascular clips, surgery within 6 weeks of entry into the study, coronary stent implanted within 8 weeks prior to the time of the intended MRI, etc...)
  • Gadolinium intolerance
  • History of ischemic cerebrovascular disorders (e.g., stroke, ) or ischemia of the spinal cord
  • History or known presence of central nervous system (CNS) or spinal cord tumor (e.g., meningioma, glioma)
  • History or known presence of potential metabolic causes of myelopathy (e.g., untreated vitamin B12 deficiency)
  • History or known presence of infectious causes of myelopathy (e.g., syphilis, Lyme disease, human T-lymphotropic virus 1 (HTLV-1), herpes zoster myelopathy)
  • History of genetically inherited progressive CNS degenerative disorder (e.g., hereditary paraparesis; MELAS [mitochondrial myopathy, encephalopathy, lactic acidosis, stroke] syndrome)
  • Neuromyelitis optica
  • History or known presence of systemic disorders potentially causing progressive neurologic disease (e.g., lupus, anti-phospholipid antibody syndrome, Sjogren's syndrome, Behçet's disease, sarcoidosis)
  • History of severe, brain or spinal cord trauma (e.g., cerebral contusion, spinal cord compression)
  • Vulnerable patients (Patient referred to in Articles L. 1121-5 to L. 1121-8 and L. 1122-1-2 of the French Public Health Code)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
423 participants (actual)

Study arms

  • Experimental
    Ocrelizumab Treatment Cycles

    Each participant will receive an initial dose of two 300 mg infusions of Ocrelizumab each separated by 14 days followed by one single dose of 600 mg 24 weeks after the initial dose.

    Drug: Ocrelizumab 300 mg · Drug: Ocrelizumab 600 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of participants free of disease activity

    This outcome measure evaluates the impact of ocrelizumab on disease activity in participants with active Relapsing Multiple Sclerosis (RMS). Freedom of disease activity is defined as participant without any relapse from enrollment to Week 48 and without T1 Gadolinium-enhancing lesion detected by brain MRI at Week 48 and without any new and/or enlarging T2 lesion detected by brain MRI at Week 48.

    Time frame: From Enrollment to Week 48

Secondary outcomes

  1. Annualized relapse rate

    Annualized relapse rate is defined as the total number of clinical relapses divided by the number of participant-years of study treatment exposure. This outcome measure describes the efficacy of ocrelizumab in active RMS participants.

    Time frame: At Week 48

  2. Percentage of participants with stable, improved, or worsened expanded disability status scale (EDSS)

    This outcome measure describes the efficacy of ocrelizumab in active RMS participants.

    Time frame: From Enrollment to Week 48

  3. Percentage of participants with confirmed disability progression at Week 24 (CDP24)

    This outcome measure describes the efficacy of ocrelizumab in active RMS participants.

    Time frame: At Week 48

  4. Mean Change in EDSS

    This outcome measure describes the efficacy of ocrelizumab in active RMS participants.

    Time frame: From Baseline to Week 48

  5. Percentage of relapse-free RMS participants

    This outcome measure describes the efficacy of ocrelizumab in active RMS participants.

    Time frame: From Enrollment to Week 24 and Week 48

  6. Percentage of participants with no T1 gadolinium-enhancing lesion and no new and/or enlarging T2 lesion as detected by brain MRI

    This outcome measure describes the efficacy of ocrelizumab in active RMS participants.

    Time frame: At Week 48

  7. Percentage of participants with no T1 gadolinium-enhancing lesion as detected by brain MRI

    This outcome measure describes the efficacy of ocrelizumab in active RMS participants.

    Time frame: At Week 48

  8. Percentage of participants with no new and/or enlarging T2 lesion as detected by brain MRI

    This outcome measure evaluates the impact of ocrelizumab on disease activity in participants with active RMS.

    Time frame: At Week 48

  9. Change in the score of MS symptom severity scale (SymptoMScreen)

    This outcome measure describes the impact of ocrelizumab on patient reported outcomes (MS symptom severity, fatigue, health-related quality of life with standard and disease specific scales, work productivity, and treatment satisfaction) in active RMS patients.

    Time frame: At Week 24 and Week 48

  10. Change in the score of Modified Fatigue Impact Scale (MFIS)

    This outcome measure describes the impact of ocrelizumab on patient reported outcomes (MS symptom severity, fatigue, health-related quality of life with standard and disease specific scales, work productivity, and treatment satisfaction) in active RMS patients.

    Time frame: At Week 24 and Week 48

  11. Change in the score of EuroQol 5-Dimension Questionnaire (EQ-5D-5L with Visual Analogue Scale (VAS)) for health-related quality of life

    This outcome measure describes the impact of ocrelizumab on patient reported outcomes (MS symptom severity, fatigue, health-related quality of life with standard and disease specific scales, work productivity, and treatment satisfaction) in active RMS patients.

    Time frame: At Week 24 and Week 48

  12. Change in the score of Work Productivity and Activity Impairment scale (WPAI:SHP)

    This outcome measure describes the impact of ocrelizumab on patient reported outcomes (MS symptom severity, fatigue, health-related quality of life with standard and disease specific scales, work productivity, and treatment satisfaction) in active RMS patients.

    Time frame: At Week 24 and Week 48

  13. Change in the score of Multiple Sclerosis International Quality Of Life Questionnaire (MusiQOL)

    This outcome measure describes the impact of ocrelizumab on patient reported outcomes (MS symptom severity, fatigue, health-related quality of life with standard and disease specific scales, work productivity, and treatment satisfaction) in active RMS patients.

    Time frame: At Week 24 and Week 48

  14. Change in the score of Treatment Satisfaction Questionnaire for Medication (TSQM-14)

    This outcome measure describes the impact of ocrelizumab on patient reported outcomes (MS symptom severity, fatigue, health-related quality of life with standard and disease specific scales, work productivity, and treatment satisfaction) in active RMS patients.

    Time frame: At Week 24 and Week 48

  15. Percentage of Participants with Adverse Events (AE)

    This outcome measure describes ocrelizumab safety in active RMS patients. Severity of AEs is determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v4.0)

    Time frame: From Baseline to Week 48

07

Study locations

46 sites
  • Centre hospitalier d'Agen; Neurologie
    Agen, 47923, France
  • CHU Amiens Hopital Sud; Neurologie
    Amiens Cedex1, 80054, France
  • CHU Angers, Batiement Larrey 2, Neurologie
    Angers Cedex 9, 49933, France
  • CHU de Besancon Hopital Jean Minjoz; Service de Neurologie
    Besançon, 25030, France
  • Groupe Hospitalier Pellegrin; Service de neurochirurgie B
    Bordeaux, 33076, France
  • CHU Brest Hopital La Cavale Blanche; Neurologie
    Brest, 29609, France
  • Hopital Pierre Wertheimer; Neurologie D
    Bron, 69677, France
  • Hopital Cote De Nacre; Unite Neurologie Generale
    Caen, 14033, France
  • CH Jean Rougier; Neurologie
    Cahors, 46005, France
  • Ch De Calais; Hopital De Jour
    Calais Cedex, 62107, France
  • CHMS Site Chambery; Neurologie
    CHAMBERY Cedex, 73011, France
  • CHU Hopital Gabriel Montpied; Service de Neurologie
    Clermont Ferrand, 63003, France
  • Hôpital General - Service de neurologie; Service de neurologie
    Dijon Cedex, 21079, France
  • CH de Gonesse; Neurologie
    Gonesse, 95503, France
  • CHU de Grenoble; Neurologie
    La Tronche, 38700, France
  • Centre hospitalier Andre Mignot; Neurologie
    Le Chesnay Cedex, 78157, France
  • CH Le Mans; Neurologie
    Le Mans, 72037, France
  • Centre hospitalier de Libourne Hopital Robert Boulin; Neurologie
    Libourne Cedex, 33505, France
  • CH St Vincent de Paul
    Lille, 59000, France
  • Hopital Roger Salengro; Service de Neurologie
    Lille, France
  • CHU Dupruytren - Limoges; Neurologie
    Limoges, 87042, France
  • Hopital européen de Marseille; Neurologie
    Marseille, 13003, France
  • CHU de la Timone - Hopital d Adultes; Service de Neurologie
    Marseille, 13005, France
  • Fondation Hopital Saint Joseph; Neurologie
    Marseille, 13285, France
  • Gh De Meaux; Neurologie
    Meaux, 77104, France
  • Centre hospitalier Annecy Genevois Site St Julien; Neurologie
    Metz Tessy, 74370, France
  • Centre hospitalier de Montlucon; Neurologie
    Montlucon, 03100, France
  • Hopital Gui de Chauliac; Neurologie
    Montpellier, 34295, France
  • Centre hospitalier de Mulhouse Hopital Emile Muller; Neurologie
    Mulhouse Cedex 1, 68070, France
  • Hopital Central - CHU de Nancy; Service de Neurologie
    Nancy, 54035, France
  • Hôpital Guillaume et René Laënnec; Service Neurologie
    Nantes, 44805, France
  • Hôpital Pasteur; Service de Neurologie
    Nice, 06002, France
  • CHU de Nîmes Hopital Caremeau; Service de Neurologie
    Nimes, 30900, France
  • Groupe Hospitalier Paris Saint Joseph; Service de Neurologie et Neurovasculaire
    Paris, 75014, France
  • Fondation Rothschild; Service de Neurologie
    Paris, 75019, France
  • Hopital Saint Antoine; Neurologie
    Paris, 75571, France
  • CHU Poitiers - La Milétrie; Neurologie
    Poitiers, 86021, France
  • Centre Hospitalier de Cornouaille; Neurologie
    Quimper, 29000, France
  • Hopital Pontchaillou
    Rennes, 35033, France
  • Hôpital Charles Nicolle; Service de Neurologie
    Rouen, 76031, France
  • CHU Saint Etienne - Hôpital Nord; Neurologie
    Saint-priest-en-jarez, 42270, France
  • Hopital Civil de Strasbourg; Service de Neurologie
    Strasbourg, 67091, France
  • Hopital Foch; Neurologie
    Suresnes, 92151, France
  • HIA de Toulon hôpital militaire; Neurologie
    Toulon, 83041, France
  • Centre hospitalier Guy Chatiliez de Tourcoing; Neurologie
    Tourcoing Cedex, 59208, France
  • Centre hospitalier de Valence; Neurologie
    Valence Cedex 9, 26953, France
08

References and documents

Publications

  • Manchon E, Laplaud D, Vukusic S, Labauge P, Moreau T, Kobelt G, Grouin JM, Lotz M, Pau D, Christine LF. Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study. Mult Scler Relat Disord. 2022 Dec;68:104109. doi: 10.1016/j.msard.2022.104109. Epub 2022 Aug 13. PubMed 36007299 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in Feb 2021, 30 months.

Of 36 industry-sponsored phase 4 interventional studies under Multiple Sclerosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 37. This study's 30 months is close to that.

Counting every sponsor, half of 69 studies reached it within 34 months; a quarter within 23 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2018
First posted
Jul 17, 2018
StartActual
Aug 6, 2018
Primary completionActual
Feb 15, 2021
CompletionActual
Feb 15, 2021
Last update
Jan 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03589105
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 17, 2018
Start date
Aug 6, 2018
Primary completion
Feb 15, 2021
Completion
Feb 15, 2021
Last update
Jan 11, 2022

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ocrelizumab

Start the discussion